<div id="readability-page-1"><p>Friedenthal Financial bought a new stake in shares of  IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,657 shares of the company's stock, valued at approximately $1,059,000.</p><div><p><span></span><span>Get <strong>IDEXX Laboratories</strong> alerts:</span></p></div><ul><li>Bullish or Bearish? Vetting Animal Health Care Stocks</li></ul><p>Several other institutional investors and hedge funds also recently modified their holdings of the business. STF Management LP lifted its holdings in  IDEXX Laboratories by 1.3% in the second quarter. STF Management LP now owns 1,240 shares of the company's stock worth $665,000 after purchasing an additional 16 shares during the period.  Clearstead Trust LLC increased its stake in  IDEXX Laboratories by 1.1% during the 2nd quarter. Clearstead Trust LLC now owns 1,515 shares of the company's stock valued at $813,000 after buying an additional 16 shares during the period.  Stratos Wealth Partners LTD. raised its position in shares of  IDEXX Laboratories by 1.7% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,051 shares of the company's stock worth $564,000 after buying an additional 18 shares in the last quarter.  Red Spruce Capital LLC lifted its stake in shares of  IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company's stock worth $912,000 after acquiring an additional 19 shares during the period.  Finally, Huntington National Bank boosted its holdings in shares of  IDEXX Laboratories by 0.5% in the second quarter. Huntington National Bank now owns 3,651 shares of the company's stock valued at $1,958,000 after acquiring an additional 19 shares in the last quarter. Institutional investors own  87.84% of the company's stock. </p><h2>Wall Street Analyst Weigh In</h2><p>Several equities research analysts recently commented on IDXX shares. Wall Street Zen cut IDEXX Laboratories from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a report on Saturday, November 29th. Stifel Nicolaus  set a $775.00 price objective on IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings cut IDEXX Laboratories from a &#34;buy (b-)&#34; rating to a &#34;hold (c+)&#34; rating in a research note on Monday. JPMorgan Chase &amp; Co. boosted their price target on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the stock an &#34;overweight&#34; rating in a research report on Tuesday, November 4th. Finally, UBS Group upped their price target on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the company a &#34;neutral&#34; rating in a report on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating and four have issued  a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $763.50.</p><p><b>Check Out Our Latest Research Report on IDXX</b></p><h2>IDEXX Laboratories Trading Down 2.8%</h2><p>NASDAQ:IDXX opened at $682.31 on Wednesday. The company has a quick ratio of 0.87, a current ratio of 1.18 and a debt-to-equity ratio of 0.24. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The firm has a market capitalization of $54.48 billion, a price-to-earnings ratio of 54.11, a price-to-earnings-growth ratio of 4.19 and a beta of 1.67. The stock has a fifty day simple moving average of $692.65 and a 200 day simple moving average of $629.36. </p><p>IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the company earned $2.80 EPS. The business's revenue for the quarter was up 13.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS.  Sell-side analysts forecast that  IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year. </p><h2>Insider Activity at IDEXX Laboratories</h2><p>In related news, EVP Nimrata Hunt sold 9,425 shares of the firm's stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $703.34, for a total value of $6,628,979.50. Following the completion of the transaction, the executive vice president owned 21,149 shares of the company's stock, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own  0.98% of the company's stock. </p><h2>About IDEXX Laboratories</h2> (Free Report)<p>IDEXX Laboratories, Inc <span>NASDAQ: IDXX<span></span></span> is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.  </p><p>IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than IDEXX Laboratories</li><li>The boring AI play that could pay up to $4,290 monthly</li><li>Trump’s “real estate deal for America” explained</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>Trump Did WHAT??</li></ul><p><strong>Want to see what other hedge funds are holding IDXX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SURYWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in IDEXX Laboratories Right Now?</h2><p>Before you consider IDEXX Laboratories, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.</p><p>While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IDXX

<p>Friedenthal Financial acquired 1,657 shares of IDEXX Laboratories, valued at $1,059,000, during the 3rd quarter. Analysts have mixed ratings on IDEXX, with a consensus price target of $763.50. The stock opened at $682.31, with a market cap of $54.48 billion. IDEXX reported $3.22 EPS for the quarter, exceeding estimates, and set FY 2025 guidance at 12.810-13.010 EPS.</p>

Friedenthal Financial Buys New Stake in IDEXX Laboratories, Inc. $IDXX